Clinical outcome of central nervous system metastases from breast cancer: Differences in survival depending on systemic treatment

Journal of Neuro-Oncology

Volumn 106, Issue 2, 2012, Pages 303-313

  Kim, Hee Jun ^a   Im, Seock Ah ^a   Keam, Bhumsuk ^a   Kim, Yu Jung ^b   Han, Sae Won ^a   Kim, Tae Min ^a   Oh, Do Youn ^a   Kim, Jee Hyun ^a,b   Lee, Se Hoon ^a   Chie, Eui Kyu ^a   Han, Wonshik ^a   Kim, Dong Wan ^a   Kim, Tae You ^a   Noh, Dong Young ^a   Heo, Dae Seog ^a   Park, In Ae ^a   Bang, Yung Jue ^a   Ha, Sung Whan ^a  

^a Seoul National University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Advanced breast cancer; CNS metastases; Prognostic factor

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; LAPATINIB; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL FEATURE; CONTROLLED STUDY; GAMMA KNIFE RADIOSURGERY; HEALTH STATUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENINGEAL METASTASIS; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PROGNOSIS; RETROSPECTIVE STUDY; SOUTH KOREA; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOSURGERY; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 82955235724     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0664-8     Document Type: Article

References (42)

1. EL Chang S Lo 2003 Diagnosis and management of central nervous system metastases from breast cancer Oncologist 8 398 410 14530493 10.1634/ theoncologist.8-5-398 (Pubitemid 37238868)
2. AB Lassman LM DeAngelis 2003 Brain metastases Neurol Clin 21 1 23 12690643 10.1016/S0733-8619(02)00035-X vii (Pubitemid 36169343)
3. K Altundag ML Bondy NQ Mirza SW Kau K Broglio GN Hortobagyi E Rivera 2007 Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis Cancer 110 2640 2647 10.1002/cncr.23088 17960791 1:CAS:528:DC%2BD1cXitVOitA%3D%3D 10.1002/cncr.23088 (Pubitemid 350250332)
4. ES Nussbaum HR Djalilian KH Cho WA Hall 1996 Brain metastases, histology, multiplicity, surgery, and survival Cancer 78 1781 1788 10.1002/(SICI)1097- 0142(19961015)78:8<1781::AID-CNCR19>3.0.CO;2-U 8859192 1:STN:280:DyaK2s%2Fht1ektQ%3D%3D 10.1002/(SICI)1097-0142(19961015)78:8<1781:: AID-CNCR19>3.0.CO;2-U (Pubitemid 26330907)
5. Kim HJ, Hong S, Kim S, Kim JH, Kim IH, Park CI, Ha SH, Wu HG, Kang WS (2002) Treatment outcome of brain metastasis after the cranial radiotherapy followed by fractionated stereotactic radiotherapy and its prognostic factors. Cancer Res Treat 34(4):284-288
6. W Boogerd VW Vos AA Hart G Baris 1993 Brain metastases in breast cancer; natural history, prognostic factors and outcome J Neurooncol 15 165 174 8509821 1:STN:280:DyaK3s3os1KmtQ%3D%3D 10.1007/BF01053937 (Pubitemid 23136031)
7. H Harputluoglu O Dizdar S Aksoy S Kilickap DS Dede Y Ozisik N Guler I Barista I Gullu M Hayran U Selek M Cengiz F Zorlu G Tekuzman K Altundag 2008 Characteristics of breast cancer patients with central nervous system metastases: a single-center experience J Natl Med Assoc 100 521 526 18507204 (Pubitemid 351717364)
8. JC Bendell SM Domchek HJ Burstein L Harris J Younger I Kuter C Bunnell M Rue R Gelman E Winer 2003 Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma Cancer 97 2972 2977 10.1002/cncr.11436 12784331 10.1002/cncr.11436 (Pubitemid 36676250)
9. P Kleihues LH Sobin 2000 World Health Organization classification of tumors Cancer 88 2887 10.1002/1097-0142(20000615)88:12<2887::AID-CNCR32>3. 0.CO;2-F 10870076 1:STN:280:DC%2BD3czivFyktw%3D%3D 10.1002/1097-0142(20000615) 88:12<2887::AID-CNCR32>3.0.CO;2-F (Pubitemid 30417954)
10. Y Tsukada A Fouad JW Pickren WW Lane 1983 Central nervous system metastasis from breast carcinoma. Autopsy study Cancer 52 2349 2354 6640506 1:STN:280:DyaL2c%2FlsV2qtg%3D%3D 10.1002/1097-0142(19831215)52:12<2349::AID- CNCR2820521231>3.0.CO;2-B (Pubitemid 14205961)
11. L Gaspar C Scott M Rotman S Asbell T Phillips T Wasserman WG McKenna R Byhardt 1997 Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials Int J Radiat Oncol Biol Phys 37 745 751 9128946 1:STN:280:DyaK2s3nsFSmsA%3D%3D 10.1016/S0360-3016(96)00619-0 (Pubitemid 27181303)
12. AJ Evans JJ James EJ Cornford SY Chan HC Burrell SE Pinder E Gutteridge JF Robertson J Hornbuckle KL Cheung 2004 Brain metastases from breast cancer: identification of a high-risk group Clin Oncol (R Coll Radiol) 16 345 349 1:STN:280:DC%2BD2cvjsF2lsQ%3D%3D 10.1016/j.clon.2004.03.012 (Pubitemid 38967255)
13. DG Hicks SM Short NL Prescott SM Tarr KA Coleman BJ Yoder JP Crowe TK Choueiri AE Dawson GT Budd RR Tubbs G Casey RJ Weil 2006 Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR Am J Surg Pathol 30 1097 1104 10.1097/01.pas.0000213306.05811.b9 16931954 (Pubitemid 44299342)
14. KD Miller T Weathers LG Haney R Timmerman M Dickler J Shen GW Sledge Jr 2003 Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival Ann Oncol 14 1072 1077 12853349 1:STN:280:DC%2BD3szitlCrtg%3D%3D 10.1093/annonc/mdg300 (Pubitemid 36950171)
15. YL Tham K Sexton R Kramer S Hilsenbeck R Elledge 2006 Primary breast cancer phenotypes associated with propensity for central nervous system metastases Cancer 107 696 704 10.1002/cncr.22041 16826579 10.1002/cncr.22041 (Pubitemid 44232661)
16. J Souglakos L Vamvakas S Apostolaki M Perraki Z Saridaki I Kazakou A Pallis C Kouroussis N Androulakis K Kalbakis G Millaki D Mavroudis V Georgoulias 2006 Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status Breast Cancer Res 8 R36 10.1186/bcr1516 16846533 10.1186/bcr1516 (Pubitemid 44057563)
17. Bae SH, Choi DH, Huh SJ, Lim DH, Park W, Nam H, Yang JH, Nam SJ, Lee JE, Im YH, Ahn JS, Park YH (2011) Incidence of brain metastasis and related subtypes in patients with breast cancer receiving adjuvant radiation therapy after surgery. J Breast Cancer 14(S):S57-S63
18. R Soffietti R Ruda E Trevisan 2008 Brain metastases: current management and new developments Curr Opin Oncol 20 676 684 10.1097/CCO.0b013e32831186fe 18841050 10.1097/CCO.0b013e32831186fe
19. NU Lin V Dieras D Paul D Lossignol C Christodoulou HJ Stemmler H Roche MC Liu R Greil E Ciruelos S Loibl S Gori A Wardley D Yardley A Brufsky JL Blum SD Rubin B Dharan K Steplewski D Zembryki C Oliva D Roychowdhury P Paoletti EP Winer 2009 Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer Clin Cancer Res 15 1452 1459 10.1158/1078-0432.CCR-08-1080 19228746 1:CAS:528:DC%2BD1MXitVOktLo%3D 10.1158/1078-0432.CCR-08-1080
20. S Sutherland S Ashley D Miles S Chan A Wardley N Davidson R Bhatti M Shehata H Nouras T Camburn SR Johnston 2010 Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases-the UK experience Br J Cancer 102 995 1002 10.1038/sj.bjc.6605586 20179708 1:CAS:528:DC%2BC3cXjt1ynu70%3D 10.1038/sj.bjc.6605586
21. HS Han JS Kim JH Park YK Jeon KW Lee DY Oh JH Kim SY Park SA Im TY Kim IA Park YJ Bang 2009 Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy J Korean Med Sci 24 910 917 10.3346/jkms.2009.24.5.910 19794992 1:CAS:528:DC%2BD1MXhtleqt7jE 10.3346/jkms.2009.24.5.910
22. B Keam SA Im HJ Kim DY Oh JH Kim SH Lee EK Chie W Han DW Kim N Cho WK Moon TY Kim IA Park DY Noh DS Heo SW Ha YJ Bang 2009 Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy Breast Cancer Res Treat 116 153 160 10.1007/s10549-008-0160-9 18787948 1:CAS:528:DC%2BD1MXntFakur8%3D 10.1007/s10549-008-0160-9
23. A Lebeau D Deimling C Kaltz A Sendelhofert A Iff B Luthardt M Untch U Lohrs 2001 Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization J Clin Oncol 19 354 363 11208826 1:CAS:528:DC%2BD3MXhtVekt78%3D (Pubitemid 32112846)
24. Tsao MN, Lloyd N, Wong R, Chow E, Rakovitch E, Laperriere N (2006) Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev 3: CD003869 doi: 10.1002/14651858.CD003869.pub2
25. D Rades R Lohynska T Veninga LJ Stalpers SE Schild 2007 Evaluation of 2 whole-brain radiotherapy schedules and prognostic factors for brain metastases in breast cancer patients Cancer 110 2587 2592 10.1002/cncr.23082 17893909 10.1002/cncr.23082 (Pubitemid 350174946)
26. WA Bleyer 1977 Methotrexate: clinical pharmacology, current status and therapeutic guidelines Cancer Treat Rev 4 87 101 329989 1:STN:280: DyaE2s3ktl2ntg%3D%3D 10.1016/S0305-7372(77)80007-8 (Pubitemid 8146048)
27. RB D'Agostino Jr 1998 Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 2265 2281 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B 9802183 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B (Pubitemid 28466823)
28. JK Lunceford M Davidian 2004 Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study Stat Med 23 2937 2960 10.1002/sim.1903 15351954 10.1002/sim.1903 (Pubitemid 39200133)
29. W Boogerd O Dalesio EM Bais JJ van der Sande 1992 Response of brain metastases from breast cancer to systemic chemotherapy Cancer 69 972 980 1735089 1:STN:280:DyaK387js1ensA%3D%3D 10.1002/1097-0142(19920215)69:4<972::AID- CNCR2820690423>3.0.CO;2-P
30. Niwinska A, Murawska M, Pogoda K (2010) Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases. Cancer doi: 10.1002/cncr.25391
31. R Bartsch A Rottenfusser C Wenzel K Dieckmann U Pluschnig G Altorjai M Rudas RM Mader R Poetter CC Zielinski GG Steger 2007 Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer J Neurooncol 85 311 317 10.1007/s11060-007-9420-5 17557136 1:CAS:528:DC%2BD2sXhsVygt77E 10.1007/s11060-007-9420-5 (Pubitemid 350142522)
32. D Rosner T Nemoto WW Lane 1986 Chemotherapy induces regression of brain metastases in breast carcinoma Cancer 58 832 839 3755076 1:STN:280: DyaL283ksVOjtg%3D%3D 10.1002/1097-0142(19860815)58:4<832::AID- CNCR2820580404>3.0.CO;2-W (Pubitemid 16035278)
33. A DiStefano Y Yong Yap GN Hortobagyi GR Blumenschein 1979 The natural history of breast cancer patients with brain metastases Cancer 44 1913 1918 498057 1:STN:280:DyaL3c%2FksVKhsw%3D%3D 10.1002/1097-0142(197911)44:5<1913:: AID-CNCR2820440554>3.0.CO;2-D (Pubitemid 10141974)
34. DW Andrews CB Scott PW Sperduto AE Flanders LE Gaspar MC Schell M Werner-Wasik W Demas J Ryu JP Bahary L Souhami M Rotman MP Mehta WJ Curran Jr 2004 Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial Lancet 363 1665 1672 10.1016/S0140-6736(04)16250-8 15158627 10.1016/S0140-6736(04)16250-8 (Pubitemid 38670323)
35. H Aoyama H Shirato M Tago K Nakagawa T Toyoda K Hatano M Kenjyo N Oya S Hirota H Shioura E Kunieda T Inomata K Hayakawa N Katoh G Kobashi 2006 Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial JAMA 295 2483 2491 10.1001/jama.295.21.2483 16757720 1:CAS:528: DC%2BD28XlsV2ltbo%3D 10.1001/jama.295.21.2483 (Pubitemid 43854963)
36. PK Sneed JH Suh SJ Goetsch SN Sanghavi R Chappell JM Buatti WF Regine E Weltman VJ King JC Breneman PW Sperduto MP Mehta 2002 A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases Int J Radiat Oncol Biol Phys 53 519 526 12062592 10.1016/S0360-3016(02)02770-0 (Pubitemid 34626488)
37. DJ Stewart NZ Mikhael RC Nair S Kacew V Montpetit A Nanji JA Maroun K Howard 1988 Platinum concentrations in human autopsy tumor samples Am J Clin Oncol 11 152 158 3358362 1:STN:280:DyaL1c7ptFOqsA%3D%3D 10.1097/00000421- 198804000-00013 (Pubitemid 18099010)
38. M van Vulpen HB Kal MJ Taphoorn SY El-Sharouni 2002 Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review) Oncol Rep 9 683 688 12066192
39. H Hikino T Yamada K Johbara N Obayashi N Ozaki 2006 Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse Breast 15 97 99 10.1016/j.breast.2005.03.006 16005228 10.1016/j.breast.2005.03.006 (Pubitemid 43210556)
40. LR Rogers SE Remer S Tejwani 2004 Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy Neuro Oncol 6 63 64 10.1215/S1152851703000334 14769142 10.1215/S1152851703000334 (Pubitemid 38139641)
41. JF Mata JM Garcia-Manteiga MP Lostao S Fernandez-Veledo E Guillen-Gomez IM Larrayoz J Lloberas FJ Casado M Pastor-Anglada 2001 Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug Mol Pharmacol 59 1542 1548 11353816 1:CAS:528:DC%2BD3MXktVahtrk%3D (Pubitemid 32510121)
42. EE Lower DR Drosick R Blau L Brennan W Danneman DK Hawley 2003 Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival Clin Breast Cancer 4 114 119 12864939 1:CAS:528:DC%2BD3sXmt1Olsrk%3D 10.3816/CBC.2003.n.016 (Pubitemid 36939417)